表紙
市場調査レポート

主要先進国の乳癌治療薬市場

Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence

発行 GBI Research 商品コード 350754
出版日 ページ情報 英文 170 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
主要先進国の乳癌治療薬市場 Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence
出版日: 2015年12月15日 ページ情報: 英文 170 Pages
概要

世界の乳癌治療薬市場は、2014年の104億米ドルから、2021年には172億米ドルまで増加し、CAGRで7.3%の成長が予測されています。

当レポートでは、主要先進国における乳癌治療薬市場について調査分析し、市場の概要、上市製品、パイプライン製品、市場予測、取引と戦略的統合などについて、体系的な情報を提供しています。

第1章 目次

第2章 イントロダクション

  • 疾患の概要
  • 症状
  • 病因
  • 病態生理
  • 疫学
  • 診断と分類
  • 予後と病期
  • 治療の選択肢
  • 治療のガイドライン

第3章 上市製品

  • 概要
  • 結論

第4章 パイプライン製品

  • パイプライン製品
  • 臨床試験
  • 競合の臨床試験メトリクス分析

第5章 パイプラインにおける有望薬の候補

  • Abemaciclib - Eli Lily
  • Buparlisib - Novartis
  • NeuVax (nelipepimut-S) - Galena Biopharma
  • Niraparib - Tesaro
  • Lynparza (Olaparib) - AstraZeneca
  • Veliparib - AbbVie
  • Neratinib - Puma Biotechnology
  • Ribociclib - Novartis
  • Talazoparib - BioMarin
  • Alpelisib - Novartis
  • Atezolizumab - Roche
  • Entinostat - Syndax
  • Margetuximab - MacroGenics
  • Taselisib - Genentech
  • OBI-822/821 - OBI Pharma
  • パイプライン製品のヒートマップ

第6章 市場予測

  • 地域市場
  • 世界市場
  • 北米
  • 欧州5大市場
  • 日本

第7章 促進要因と障壁

  • 促進要因
  • 障壁

第8章 取引と戦略的統合

  • ライセンス取引
  • 共同開発取引

第9章 付録

図表

目次
Product Code: GBIHC379MR

Executive Summary

Breast cancer, a malignant neoplasm, is the second most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. The number of women diagnosed with breast cancer has increased over the past few decades, but the number of deaths has declined due to earlier diagnosis and better treatment options.

Breast cancer treatment has been revolutionized in the past four decades, especially with increasing usage of targeted therapies. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies, and targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.

Scope

The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.

  • What are the competitive advantages of the existing novel drugs?
  • With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.
  • Which classes of novel drugs are most prominent within the pipeline?
  • Is there strong potential for the pipeline to address unmet needs within the breast cancer market?

Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.

  • How do failure rates vary by product stage of development, molecule type, and mechanism of action?
  • How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?

Over the 2014-2021 forecast period, the breast cancer therapeutics market in the eight major markets is expected to increase in value at a CAGR of 7.3%, from $10.4 billion to over $17.2 billion.

  • Which markets make the most significant contribution to the current market size?
  • What are the epidemiology trends in these markets?
  • Will new market entrants lead to substantial changes in annual therapy costs?
  • How will different treatment usage patterns impact growth in the eight major markets?

Rising breast cancer incidence and new product approvals will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.

  • Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
  • Which patent expirations will have the most significant impact on the market?

Reasons to buy

This report will enable you to -

  • Understand the clinical context of breast cancer by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
  • Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
  • Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
  • Consider market opportunities and potential risks by examining trends in breast cancer clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
  • Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in breast cancer by examining clinical trial data and multi-scenario product forecast projections.
  • Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan.
  • Discover trends in licensing and co-development deals concerning breast cancer products and identify the major strategic consolidations that have shaped the commercial landscape.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Symptoms
  • 2.3. Etiology
  • 2.4. Pathophysiology
  • 2.5. Epidemiology
  • 2.6. Diagnosis and Classification
  • 2.7. Prognosis and Disease Staging
  • 2.8. Treatment Options
    • 2.8.1. Surgery and Radiation Therapy
    • 2.8.2. Chemotherapy
    • 2.8.3. Hormonal Therapies
    • 2.8.4. Targeted Therapies
    • 2.8.5. Resistance to Pharmacological Therapies
  • 2.9. Treatment Guidelines

3. Marketed Products

  • 3.1. Overview
    • 3.1.1. Herceptin (trastuzumab)-Genentech
    • 3.1.2. Perjeta (pertuzumab)-Genentech
    • 3.1.3. Afinitor (everolimus)-Novartis
    • 3.1.4. Tykerb/ Tyverb (lapatinib ditosylate monohydrate)-Novartis
    • 3.1.5. Ibrance (palbociclib)-Pfizer
    • 3.1.6. Ixempra (ixabepilone)-Bristol-Myers Squibb
    • 3.1.7. Halaven (eribulin mesylate)-Eisai
    • 3.1.8. Avastin (bevacizumab)-Genentech
    • 3.1.9. Kadcyla (ado-trastuzumab emtansine)-Genentech
    • 3.1.10. Marketed Products Heatmap
    • 3.1.11. Measuring the Effectiveness of Treatment
  • 3.2. Conclusion

4. Pipeline Products

  • 4.1. Pipeline Products
    • 4.1.1. Overall Pipeline
    • 4.1.2. Pipeline by Molecular Target
  • 4.2. Clinical Trials
    • 4.2.1. Failure Rate
    • 4.2.2. Patient Enrollment and Clinical Trial Size
    • 4.2.3. Duration
  • 4.3. Competitive Clinical Trials Metrics Analysis

5. Promising Drug Candidates in Pipeline

  • 5.1. Abemaciclib-Eli Lily
    • 5.1.1. Abemaciclib Forecast
  • 5.2. Buparlisib-Novartis
    • 5.2.1. Buparlisib Forecast
  • 5.3. NeuVax (nelipepimut-S)-Galena Biopharma
    • 5.3.1. NeuVax Forecast
  • 5.4. Niraparib-Tesaro
    • 5.4.1. Niraparib Forecast
  • 5.5. Lynparza (Olaparib)-AstraZeneca
    • 5.5.1. Lynparza Forecast
  • 5.6. Veliparib-AbbVie
    • 5.6.1. Veliparib Forecast
  • 5.7. Neratinib-Puma Biotechnology
    • 5.7.1. Neratinib Forecast
  • 5.8. Ribociclib-Novartis
    • 5.8.1. Ribociclib Forecast
  • 5.9. Talazoparib-BioMarin
  • 5.10. Alpelisib-Novartis
  • 5.11. Atezolizumab-Roche
  • 5.12. Entinostat-Syndax
  • 5.13. Margetuximab-MacroGenics
  • 5.14. Taselisib-Genentech
  • 5.15. OBI-822/821-OBI Pharma
  • 5.16. Heat Map for Pipeline Products

6. Market Forecast to 2021

  • 6.1. Geographical Markets
  • 6.2. Global Market
  • 6.3. North America
    • 6.3.1. Treatment Usage Patterns
    • 6.3.2. Annual Cost of Therapy
    • 6.3.3. Market Size
  • 6.4. Five Leading European Markets
    • 6.4.1. Treatment Usage Patterns
    • 6.4.2. Annual Cost of Therapy
    • 6.4.3. Market Size
  • 6.5. Japan
    • 6.5.1. Treatment Usage Patterns
    • 6.5.2. Annual Cost of Therapy
    • 6.5.3. Market Size

7. Drivers and Barriers for the Disease Market

  • 7.1. Drivers
    • 7.1.1. Increased Uptake of Targeted and Combination Therapies for Breast Cancer
    • 7.1.2. Growth and Aging of Western Populations
    • 7.1.3. Launch of Premium-Priced Products with Greater Efficacy than Existing Therapies
  • 7.2. Barriers
    • 7.2.1. Patent Expiries
    • 7.2.2. High Level of Competition
    • 7.2.3. Problems with the Reimbursement of Premium-Priced Therapeutics will Limit their Uptake

8. Deals and Strategic Consolidations

  • 8.1. Licensing Deals
    • 8.1.1. Sprint Bioscience Enters Licensing Agreement with Bayer HealthCare
    • 8.1.2. Takeda Enters Licensing Agreement with ImmunoGen
    • 8.1.3. Oncothyreon Enters Licensing Agreement with Array BioPharma for ONT-380
    • 8.1.4. Halozyme Therapeutics Enters Licensing Agreement with Janssen Biotech
    • 8.1.5. CTI BioPharma Enters Licensing Agreement with Servier for Pixuvri
  • 8.2. Co-development Deals
    • 8.2.1. MacroGenics Enters Agreement with Merck
    • 8.2.2. Color Genomics Partners with University of California Health
    • 8.2.3. Lycera Enters Co-development Agreement with Celgene
    • 8.2.4. Roche Holding Enters Agreement with Oryzon to Develop Epigenetics-Based Medicines
    • 8.2.5. Tracon Enters Co-development Agreement with Santen Pharma

9. Appendix

  • 9.1. All Pipeline Drugs by Phase of Development
    • 9.1.1. Discovery
    • 9.1.2. Preclinical
    • 9.1.3. IND/CTA-filed
    • 9.1.4. Phase I
    • 9.1.5. Phase II
    • 9.1.6. Phase III
    • 9.1.7. Pre-registration
  • 9.2. Market Forecasts to 2021
    • 9.2.1. Global
    • 9.2.2. US
    • 9.2.3. Canada
    • 9.2.4. UK
    • 9.2.5. France
    • 9.2.6. Germany
    • 9.2.7. Italy
    • 9.2.8. Spain
    • 9.2.9. Japan
  • 9.3. Bibliography
  • 9.4. Abbreviations
  • 9.5. Research Methodology
    • 9.5.1. Secondary Research
    • 9.5.2. Marketed Product Profiles
    • 9.5.3. Late-Stage Pipeline Candidates
    • 9.5.4. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 9.5.5. Forecasting Model
    • 9.5.6. Deals Data Analysis
  • 9.6. Contact Us
  • 9.7. Disclaimer

List of Tables

  • Table 1: Breast Cancer Therapeutics, US, Disease Stage at Diagnosis (%), 2013
  • Table 2: Breast Cancer Therapeutics, Global, Tumor, Nodes and Metastasis Staging, 2010-2013
  • Table 3: Breast Cancer Therapeutics, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013
  • Table 4: Breast Cancer Therapeutics Market, Global, Pipeline Products, Discovery, 2015
  • Table 5: Breast Cancer Therapeutics Market, Global, Pipeline Products, Preclinical, 2015
  • Table 6: Breast Cancer Therapeutics Market, Global, Pipeline Products, IND/CTA-filed, 2015
  • Table 7: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase I, 2015
  • Table 8: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase II, 2015
  • Table 9: Breast Cancer Therapeutics Market, Global, Pipeline Products, Phase III, 2015
  • Table 10: Breast Cancer Therapeutics Market, Global, Pipeline Products, Pre-registration, 2015
  • Table 11: Breast Cancer Therapeutics Market, Global, Market Forecast, 2014-2021
  • Table 12: Breast Cancer Therapeutics Market, US, Market Forecast, 2014-2021
  • Table 13: Breast Cancer Therapeutics Market, Canada, Market Forecast, 2014-2021
  • Table 14: Breast Cancer Therapeutics Market, UK, Market Forecast, 2014-2021
  • Table 15: Breast Cancer Therapeutics Market, France, Market Forecast, 2014-2021
  • Table 16: Breast Cancer Therapeutics Market, Germany, Market Forecast, 2014-2021
  • Table 17: Breast Cancer Therapeutics Market, Italy, Market Forecast, 2014-2021
  • Table 18: Breast Cancer Therapeutics Market, Spain, Market Forecast, 2014-2021
  • Table 19: Breast Cancer Therapeutics Market, Japan, Market Forecast, 2014-2021

List of Figures

  • Figure 1: Breast Cancer Therapeutics, Eight Leading Markets, Age-Standardized Incidence Rates of Breast Cancer (per 100,000), 2012
  • Figure 2: Breast Cancer Therapeutics, US, Age-Specific Incidence Rates of Breast Cancer in Women (per 100,000), 1992-2012
  • Figure 3: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stages I-III, 2015
  • Figure 4: Breast Cancer Therapeutics, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2015
  • Figure 5: Breast Cancer Therapeutics Market, Global, Heat Map
  • Figure 6: Breast Cancer Therapeutics Market, Global, Overview of Pipeline Products
  • Figure 7: Breast Cancer Therapeutics Market, Global, Molecular Target in the Pipeline
  • Figure 8: Breast Cancer Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase, 2006-2015
  • Figure 9: Breast Cancer Therapeutics Market, Global, Clinical Trial Overall Attrition Rate and Failure Rate by Phase and Molecule Type (%), 2006-2015
  • Figure 10: Breast Cancer Therapeutics Market, Global, Clinical Trial Attrition Rate and Failure Rate by Phase and Molecular Target (%), 2006-2015
  • Figure 11: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2015
  • Figure 12: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecule Type (participants), 2006-2015
  • Figure 13: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Product by Molecular target (participants), 2006-2015
  • Figure 14: Breast Cancer Therapeutics Market, Global, Clinical Trial Size per Individual Trial by Molecular Target (participants), 2006-2015
  • Figure 15: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2015
  • Figure 16: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2015
  • Figure 17: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
  • Figure 18: Breast Cancer Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Mechanism of Action
  • Figure 19: Breast Cancer Therapeutics Market, Global, Abemaciclib, Market Forecast ($m), 2020-2021
  • Figure 20: Breast Cancer Therapeutics Market, Global, Buparlisib, Market Forecast ($m), 2020-2021
  • Figure 21: Breast Cancer Therapeutics Market, Global, NeuVax, Market Forecast ($m), 2020-2021
  • Figure 22: Breast Cancer Therapeutics Market, Global, Niraparib, Market Forecast ($m), 2020-2021
  • Figure 23: Breast Cancer Therapeutics Market, Global, Lynparza, Market Forecast ($m), 2020-2021
  • Figure 24: Breast Cancer Therapeutics Market, Global, Lynparza, Market Forecast ($m), 2020-2021
  • Figure 25: Breast Cancer Therapeutics Market, Global, Neratinib, Market Forecast($m) 2020-2021
  • Figure 26: Breast Cancer Therapeutics Market, Global, Ribociclib, Market Forecast ($m), 2020-2021
  • Figure 27: Breast Cancer Therapeutics Market, Global, Pipeline Heat Map, 2015
  • Figure 28: Breast Cancer Therapeutics Market, Global, Treatment Patterns (million) and Market Size ($bn), 2014-2021
  • Figure 29: Breast Cancer Therapeutics Market, North America, Treatment Patterns ('000), 2014-2021
  • Figure 30: Breast Cancer Therapeutics Market, North America, Annual Cost of Therapy ($), 2014-2021
  • Figure 31: Breast Cancer Therapeutics Market, North America, Market Size ($bn), 2014-2021
  • Figure 32: Breast Cancer Therapeutics Market, Five Leading European Markets, Treatment Patterns ('000), 2014-2021
  • Figure 33: Breast Cancer Therapeutics Market, Five Leading European Market, Annual Cost of Therapy ($), 2014-2021
  • Figure 34: Breast Cancer Therapeutics Market, Five Leading European Markets, Market Size ($m), 2014-2021
  • Figure 35: Breast Cancer Market, Japan, Treatment Usage Patterns ('000), 2014-2021
  • Figure 36: Breast Cancer Market, Japan, Annual Cost of Therapy ($), 2014-2021
  • Figure 37: Breast Cancer Therapeutics Market, Japan, Market Size ($m), 2014-2021
  • Figure 38: Breast Cancer Therapeutics Market, Global, Licensing Deals by Region, 2006-2015
  • Figure 39: Breast Cancer Therapeutics Market, Global, Licensing Deals by Deal Value, 2006-2015
  • Figure 40: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value ($m) and Aggregate Upfront Payment Value ($m), 2006-2015
  • Figure 41: Breast Cancer Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value ($m) and Upfront Payment Value ($m), 2006-2015
  • Figure 42: Breast Cancer Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2015
  • Figure 43: Breast Cancer Therapeutics Market, Global, Co-development Deals by Region, 2006-2015
  • Figure 44: Breast Cancer Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year and Value, 2006-2015
  • Figure 45: Breast Cancer Therapeutics Market, Global, Co-development Deals by Stage of Development, 2006-2015
  • Figure 46: Breast Cancer Therapeutics Market, Global, Co-development Deals by Molecular Target, 2006-2015
Back to Top